A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-06-06

Study Completion Date

2017-09-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 DNA vaccines delivered by electroporation (EP) to female participants with HPV-16 and/or 18-positive cervical carcinoma.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3

NCT01304524

Cervical Intraepithelial Neoplasia

COMPLETED PHASE2

Therapeutic Vaccination for Patients With HPV16+ Cervical Intraepithelial Neoplasia (CIN2/3)

NCT00988559

HPV16 Positive Cervical Intraepithelial Neoplasia (CIN 2/3)

COMPLETED PHASE1

HPV DNA Vaccine Via Electroporation for HPV16 Positive Cervical Neoplasia

NCT04131413

Human Papillomavirus Type 16 Cervical Intraepithelial Neoplasia Grade II Cervical Intraepithelial Neoplasia, Grade III

RECRUITING PHASE1

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00121173

Cervical Cancer Precancerous Condition

COMPLETED PHASE1/PHASE2

Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia

NCT00054041

Cervical Cancer Cervical Intraepithelial Neoplasia Grade 3 Human Papilloma Virus Infection

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Phase I/IIa, open-label study to evaluate the safety, tolerability, and immunogenicity of INO-3112 \[VGX-3100 and INO-9012\] delivered intramuscularly by electroporation in approximately 30 female participants with biopsy-proven, Stage IB-IVB inoperable invasive cervical carcinoma associated with HPV 16 and/or 18 who have completed treatment with standard chemoradiation therapy with curative intent (Cohort I) or in participants with persistent and/or recurrent cervical cancer associated with HPV 16 and/or 18 following salvage therapy (Cohort II).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cervical Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cohort I: INO-3112: Curative Intent

Cohort I included participants with biopsy-proven, stage IB-IVB inoperable, newly diagnosed invasive cervical carcinoma associated with HPV-16 and/or HPV-18 treated with standard chemoradiation therapy with curative intent. Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.

Group Type EXPERIMENTAL

INO-3112

Intervention Type BIOLOGICAL

1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.

CELLECTRA™-5P

Intervention Type DEVICE

CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.

Cohort II: INO-3112: Salvage Therapy

Cohort II included participants with persistent and/or recurrent cervical carcinoma associated with HPV-16 and/or HPV-18 who had been treated with salvage therapy (chemotherapy and/or radiation therapy). Participants received a 4-dose series of 1.1 mL IM injection of INO-3112 followed immediately by EP with CELLECTRA™-5P.

Group Type EXPERIMENTAL

INO-3112

Intervention Type BIOLOGICAL

1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.

CELLECTRA™-5P

Intervention Type DEVICE

CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

INO-3112

1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.

Intervention Type BIOLOGICAL

CELLECTRA™-5P

CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

VGX-3100 INO-9012

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Written informed consent.
2. Histological diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma of the cervix. Not accepted are small cell, clear cell and other rare variants of the classical adenocarcinoma.
3. Histologically confirmed, Stage IB-IVB, invasive cervical carcinoma associated with HPV 16 and/or 18 and meet the following eligibility criteria for either Cohort 1 or Cohort 2.

1. Cohort 1

* Newly diagnosed inoperable cervical cancer treated with chemoradiation therapy with curative intent and life expectancy of at least 12 months as assessed by the investigator
* No CNS/spinal metastases
* Able to initiate study treatment within 2 weeks of completion of last chemoradiation treatment
2. Cohort 2

* Persistent and/or recurrent cervical cancer
* No CNS/spinal metastases
* Able to initiate study treatment at least 2 weeks but no more than 4 weeks after completion of salvage therapy
* Life expectancy of at least 12 months as assessed by the investigator
4. Electrocardiogram (ECG) with no clinically significant findings.
5. Chemistry, liver function tests, renal function, total CPK and hematology lab results must be ≤ Grade 1 at the time of screening.
6. Eastern Cooperative Oncology Group (ECOG) Performance status of ≤ 1.
7. Adequate venous access for repeated blood sampling according to the study schedule.
8. Women of child-bearing potential must have a negative serum pregnancy test and agree to remain sexually abstinent, have a partner who is sterile (i.e., vasectomy), or use two medically effective methods of contraception (e.g., oral contraception, barrier methods, spermicide, intrauterine device \[IUD\]).
9. Able and willing to comply with all study procedures.

Exclusion Criteria

1. Pregnancy or breastfeeding.
2. History of previous therapeutic HPV vaccination.
3. Prior exposure to an investigational agent or device within 30 days of signing the ICF. Of note, the participant may participate in observational studies.
4. Positive serological test for HIV, Hep B or Hep C or history of HIV infection, Hepatitis B or Hepatitis C (women with cured HCV will be allowed; participant must have had a serologic test performed within 12 months of informed consent).
5. Prior major surgery from which the participant has not yet recovered to baseline.
6. High medical risks because of non-malignant systemic disease or with active uncontrolled infection.
7. Current malignancies at other sites, with the exception of adequately treated basal or squamous cell carcinoma of the skin.
8. Congestive heart failure or prior history of New York Heart Association (NYHA) class III/ IV cardiac disease.
9. Use of topical corticosteroids at or near the intended administration site.
10. Any cardiac pre-excitation syndromes (such as Wolff-Parkinson-White).
11. History of seizures (unless seizure free for 5 years).
12. Tattoos or scars within 2 cm of the intended site of injection or if there is implanted metal within the same limb. Any device implanted in the chest (e.g., cardiac pacemaker or defibrillator) excludes the use of the deltoid muscle on the same side of the body.
13. Active drug or alcohol use or dependence.
14. Imprisonment or compulsory detainment for treatment of either a psychiatric or physical (i.e. infectious disease) illness.
15. History of immunosuppressive or autoimmune disease.
16. Any other illnesses or conditions that in the opinion of the investigator may affect the safety of the participant or limit the evaluation of a participant or any study endpoint.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No